Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Dean Elbe.
Journal of Child and Adolescent Psychopharmacology | 2015
Zachary Whitney; Heidi N. Boyda; Ric M. Procyshyn; Dean Elbe; Tyler Black; Ali Eslami; Alasdair M. Barr
OBJECTIVE In children and adolescents, the prevalence rate of mental illness is claimed to be as high as 10-20%. Effective pharmacological treatments are available for use in children, adolescents, and adults; however, most of what is known about the effects of these treatments has been confirmed in clinical studies involving adults only. Second generation antipsychotic drugs (SGAs) are the most common class of antipsychotic medication used in pediatric populations, and these drugs are increasingly being used for disorders other than psychosis. Many SGAs are routinely used in pediatric care, and the vast majority of use in this population is off label. Children, adolescents, and adults differ in age, weight, height, and metabolism, which may lead to pharmacokinetic differences in how drugs ultimately affect target tissues. The aim of this review is to summarize and evaluate the literature that investigated blood plasma levels of SGAs in youth. METHODS Plasma levels were assessed in relation to their administered dose, indication, and therapeutic range (if known). Studies were limited to those evaluating oral administration only. A systematic electronic database search for peer-reviewed articles published between 2000 and 2013 was conducted. Twenty-one articles were included in the review. Additional articles for discussion were also included throughout the article. RESULTS The only SGA that may require routine therapeutic drug monitoring (TDM) in youth given the current body of research is clozapine. Highly variable results were seen in studies of aripiprazole, olanzapine, and risperidone, indicating that more research is needed on plasma levels with these drugs. Quetiapine maintained a similar profile to that found in adults, with no dosage adjustments or indications of TDM. CONCLUSION TDM may be indicated in any circumstance in which cytochrome P450 inhibitors or inducers are coprescribed. Further research is required for establishing a sounder safety profile for SGA use in the pediatric population.
Journal of Clinical Psychopharmacology | 2014
Ric M. Procyshyn; Johnny Su; Dean Elbe; Angela Y. Liu; William J. Panenka; Jana Davidson; William G. Honer; Alasdair M. Barr
Abstract The objective of this study was to examine the prevalence and patterns of antipsychotic use in children and adolescents at the time of admission and discharge from a tertiary care inpatient psychiatric facility. This retrospective analysis included all patients 18 years and younger, who were admitted and discharged from a child and adolescent tertiary care inpatient psychiatric facility between May 1, 2008 and December 31, 2009. Data for medications at admission were obtained using a province-wide network that links all pharmacies in British Columbia, Canada to a central set of data systems, whereas data for medications at discharge were obtained using the Department of Pharmacy’s (British Columbia Children’s Hospital, Vancouver, British Columbia, Canada) inpatient computer database. Apart from antipsychotics, overall drug use included antidepressants, mood stabilizers, benzodiazepines, anticholinergics, stimulants, and sleep medications. Referral and discharge diagnoses were also examined. During the study period, 335 patients were admitted and discharged from the tertiary care inpatient psychiatric facility. Significantly, more patients were prescribed with an antipsychotic at the time of discharge from hospital compared with that of the time when they were admitted to hospital (51.6% vs 30.7%; P < 0.0001). Antidepressants were most often coprescribed with an antipsychotic at admission and discharge (32.0% vs 42.2%, respectively) followed by attention-deficit/hyperactivity disorder medications (22.3% vs 24.9% at admission and discharge, respectively) and anticonvulsants (19.4% vs 19.1% at admission and discharge, respectively). Whether the significant increase in antipsychotic use seen from the time of admission to discharge is solely attributed to clinical worsening or other variables requires further investigation.
Journal de l'Académie canadienne de psychiatrie de l'enfant et de l'adolescent | 2010
Constadina Panagiotopoulos; Rebecca Ronsley; Dean Elbe; Jana Davidson; Derryck H. Smith
Journal de l'Académie canadienne de psychiatrie de l'enfant et de l'adolescent | 2012
Dean Elbe; Zaahira Lalani
Journal de l'Académie canadienne de psychiatrie de l'enfant et de l'adolescent | 2011
Carlo G. Carandang; Rekha Jabbal; Angela MacBride; Dean Elbe
Journal de l'Académie canadienne de psychiatrie de l'enfant et de l'adolescent | 2010
Rebecca Ronsley; Dean Elbe; Derryck H. Smith; Garland Ej
Journal de l'Académie canadienne de psychiatrie de l'enfant et de l'adolescent | 2014
Dean Elbe; Dorothy Reddy
BMC Psychiatry | 2013
David Linton; Ric M. Procyshyn; Dean Elbe; Lik Hang N. Lee; Alasdair M. Barr
Journal of Psychiatry & Neuroscience | 2014
Dean Elbe; Alasdair M. Barr; William G. Honer; Ric M. Procyshyn
Journal of Child and Adolescent Psychopharmacology | 2014
Dean Elbe; Leslie Wicholas